Orthocell adds to quality of board through appointment of new executive director – Proactive Investors UK

With a leading regenerative medicine portfolio and experienced senior advisory team, Orthocell is well-positioned to drive its products into the US, EU and AU markets.

() has enhanced the quality of its board through the appointment ofexperienced medical technology executive Leslie Wise, JD, as an executive director.

A point of strength for the Perth-based regenerative medicine company is the quality of advisors on its board and the key opinion leaders with whom they are closely connected, who are central to the way they innovate and do business.

As such,Wise, who has more than 20 years of specialist experience working in US reimbursement, life scienceand medtech fields, willstrengthen the company's strategy.

Orthocell managing director Paul Anderson said Wise was ideally suited to support the next phase of the companys development.

He said: We are delighted to welcome Leslie to the Orthocell board.

"Leslie has extensive experience in securing US market access and reimbursement for medical devices as well as serving in various senior management positions across large US medical device and pharmaceutical companies.

Leslies depth of knowledge and expertise is ideally suited to our product range and the next phase of growth for Orthocell.

Wise said: I am very excited to be joining Orthocell at this pivotal stage in the companys development.

Orthocell has one of the most advanced musculoskeletal regenerative medicine portfolios globally and is poised to leverage its impressive clinical evidence to drive towards the US, EU and AUS markets.

The timing could not be better for Orthocell as the broader Orthopaedic sector moves towards biologics and minimally invasive surgeries to deliver higher quality, more efficient and cost-effective solutions.

Leslie Wise, JD,has more than 20 years of specialist experience working in US reimbursement, life scienceand medtech fields

Wise has worked for both medical device and pharmaceutical companies, including Bristol Myers-Squib, Sanofi, Biomet Orthopedics and AngioDynamics, and is currently principal of EvidenceMatters, a Global Market Access consultancy.

Her skill set includes reimbursement, value evidence generation, clinical research strategy and frontline regulatory and payer experience, she has demonstrated experience in strategically integrating outcomes research, health policy analysis, payer insight, patient preference, along with stakeholder engagement and has been instrumental in creating new standards for reimbursement in the medtech space.

In recognition of her expertise, Wise was re-appointed to the Medicare Evidence Development Coverage and Advisory Committee (MEDCAC) for 2018-2020 and She also partnered with Advamed to facilitate the MedTech Value Summit inaugural event in Minneapolis in 2019.

Go here to read the rest:
Orthocell adds to quality of board through appointment of new executive director - Proactive Investors UK